BST2 and melanoma: To further validate the prognostic value of the TIR signature obtained from the TCGA melanoma cohort, we tested this signature in an independent melanoma dataset (GSE65904)30 (Supplementary Data 3), finding that patients with high TIR risk scores had worse OS, higher risk coefficient and mortality, and lower expression levels of SEL1L3, HAPLN3, BST2, and IFITM1 than those with low TIR risk scores (Fig. 3a–d).